Balance Sheet
Cash Flow Statement
Beginning Cash BalanceBeginning Cash BalanceCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Change in Accured Expenses (2023 - 2025)

Mangoceuticals' Change in Accured Expenses history spans 3 years, with the latest figure at -$370196.0 for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 151.29% to -$370196.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$216358.0, a 131.05% decrease, with the full-year FY2025 number at -$216358.0, down 131.05% from a year prior.
  • Change in Accured Expenses hit -$370196.0 in Q4 2025 for Mangoceuticals, down from -$276656.0 in the prior quarter.
  • Over the last five years, Change in Accured Expenses for MGRX hit a ceiling of $875180.0 in Q1 2024 and a floor of -$602885.0 in Q3 2024.
  • Historically, Change in Accured Expenses has averaged $48955.7 across 3 years, with a median of $18995.0 in 2023.
  • The widest YoY moves for Change in Accured Expenses: up 6480.72% in 2024, down 1365.23% in 2024.
  • Tracing MGRX's Change in Accured Expenses over 3 years: stood at $51706.0 in 2023, then surged by 1295.85% to $721736.0 in 2024, then plummeted by 151.29% to -$370196.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for MGRX at -$370196.0 in Q4 2025, -$276656.0 in Q3 2025, and $89816.0 in Q2 2025.